Danish firm Bavarian Nordic A/S has announced that Singapore’s medicines regulatory authority, Health Sciences Authority (HSA), has approved JYNNEOS (MVA-BN) for prevention of smallpox and mpox disease in adults 18 years of age and older determined to be at high risk for smallpox or mpox infection.

This marks the transition to a full approval for JYNNEOS in Singapore, where like in many other countries, the vaccine was made available under emergency use provisions to mitigate the last mpox outbreak.

MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic is a non-replicating smallpox vaccine and the only mpox vaccine approved in the US, Switzerland and Singapore (marketed as JYNNEOS), Canada (marketed as IMVAMUNE), and the EU/EAA and United Kingdom (marketed as IMVANEX). Originally developed in collaboration with the US government to ensure the supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines, MVA-BN has been indicated for use in the general adult population in individuals considered at risk for smallpox or mpox infection.